Sign in
REVBW Stock Price, Chart, Stats & News
Revelation Biosciences, Inc.
Save
Revelation Biosciences, Inc. (REVBW) does not currently pay a dividend.
30,213
Market cap
–
Current P/E
–
Forward P/E
REVBW chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -0.08% |
ROE | -0.40% |
D/E | 0.08x |
Interest coverage ratio | – |
REVBW valuation
P/E | – |
P/S | – |
P/B | 0.00x |
P/CF | -0.85x |
P/FCF | -0.20x |
P/OCF | -0.85x |
PEG | -0.04x |
EV multiple | 550.50x |
About
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering immunology-based therapies and diagnostic tools aimed at preventing and treating a range of illnesses. Their flagship therapeutic, REVTx-99, is an intranasal immunomodulator designed to both prevent and treat a broad spectrum of respiratory viral infections, including SARS-CoV-2 (and its variants), influenza A and B, parainfluenza, rhinovirus, and RSV. Furthermore, its potential extends to addressing allergic rhinitis and chronic nasal congestion.
Similar securities
Based on sector and market capitalization
Report issue